Abstract: The present invention relates to methods for the diagnosis of impaired cardiac function/heart disease. The present invention provides a method of diagnosing heart disease in a subject, said method comprising determining the level of CgB or SgII, or fragments thereof, in a body fluid of said subject. Such methods can also be used to determine the clinical severity or prognosis of heart disease in a subject.

Abstract: The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II ? chain; (ii) all or part of the extracellular portion of an MHC class II ? chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the ?2 domain of said ? chain and the ?2 domain of said ? chain, wherein said cysteine residues are not present in native MHC class II ?2 and ?2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects.

Abstract: The invention relates to segmenting blood vessels in perfusion MR images, more particularly, the invention relates to automated vessel removal in identified tumor regions prior to tumor grading. Pixels from a perfusion related map from dynamic contrast enhancement (DCE) MR images are clustered into arterial pixels and venous pixels by e.g. a k-means class cluster analysis. The analysis applies parameters representing the degree to which the tissue entirely consists of blood (such as relative blood volume (rBV), peak enhancement (?R2max) and/or post first-pass enhancement level (?R2p)) and parameters representing contrast arrival time at the tissue (such as first moment of the area (fmAUC) and/or contrast arrival time (T0)). The artery and venous pixels are used to form a vessel mask. The invention also relates to a computer aided diagnostic (CAD) system for tumor grading, comprising automated tumor segmentation, vessel segmentation, and tumor grading.

Abstract: Proton conductivity has been shown in acceptor-doped rare earth orthoniobates and tantalates (LnNbO4 and LnTaO4) at high temperatures and in a humid atmosphere. The use of the materials as an electrolyte in a laboratory-scale fuel cell and water vapor sensor has been demonstrated. Results for Ca-doped LaNbO4 are given as examples.

Abstract: The present invention relates ultrasound positioning systems (300), and in particular to ultrasound positioning systems that utilize at least one stationary array-based ultrasound transmitter (310) in combination with portable receivers (330,331) to provide a safe and robust positioning system.

Abstract: The present invention relates to methods for determining the prognosis of a condition which requires critical care, said methods comprising determining the level of SgII, or fragments thereof in a subject. The methods of the invention can also be used to determine whether an individual is suffering from a condition which requires critical care and determining the severity of a condition which requires critical care.

Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.

Abstract: The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

Abstract: An embodiment of the invention is to make possible a non-invasive grading of a tumor based on parameters determined from a frequency distribution (histogram) of values in a map representing cerebral blood volume (CBV) or cellular metabolism in the tumor. The method is especially applicable to brain tumors such as gliomas where histological grading is difficult. The invention provides a precise and consistent grading since it relies on values selected from the whole tumor (not just from hot spots); since it takes the diversity or heterogeneity of the vascularization into account by analyzing the frequency distribution (not just a mean value); and since it involves and allows for a more automated procedure wherein any subjective contributions from human operators is not critical to the resulting grading. CBV maps may be obtained by perfusion imaging using MRI or CT scanning. Cellular metabolism maps may be obtained from a glucose metabolism map obtained by positron emission tomography (PET).

Abstract: The present inventors here present a novel strategy for identification of RNA transcript variants and demonstrate that these can be correlated to disease states in mammals such as cancer. In particular, the transcript variants show prevalence and specificity to cancer, and thus also show clinical applicability in e.g. cancer diagnostics and prognostics, treatment and therapeutics. The present inventors have identified RNA transcript variants of VNN1 that can be used as biomarkers. The RNA transcript variant may also be used as biomarkers for diagnosing, prognosing, and/or monitoring a cancer.

Abstract: The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m2/g or if functionalized, having a surface area of at least 500 m2/g.

Abstract: Provided herein are systems, uses, and processes relating to network communications. For example, provided herein are systems, uses, and processes for increasing transmission efficiency by removing redundancy from single source multiple destination transfers.

Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Abstract: A process for the preparation of thin films of an organic-inorganic nature comprising growing with a gas phase deposition technique preferable the ALCVD (atomic layer chemical vapour deposition) technique. As an example, trimethylaluminium (TMA), hydroquinone (Hq) and phloroglucinol (PhI) have been used as precursors to fabricate thin films of aluminium benzene oxides constructing a hybrid type film. Further thin films with a hybrid nature are described. These films can be used as an optical material, a pressure sensor, a gas sensor, temperature sensor, magnetic field sensor, electric field sensor, a piezoelectric material, a magnetic material, a semiconductor material and as an electric insulating material.

Abstract: A peptide which can adopt a 310-helical conformation in which the side chains of two amino acid residues in the peptide backbone are linked by a group comprising an aromatic 5-membered ring.

Abstract: The invention provides a method, an image analysis software product, and a system for medical imaging analysis for estimating contrast agent extravasation in contrast agent based perfusion imaging such as MRI dynamic contrast enhanced (DCE) imaging, and in particular correction, compensation, or visualization of extravascular leakage of contrast agent in tumors. According to the invention, the effect of extravasation is directly manifested in the tail part of an observed, apparent residue function, R?(t), obtained directly by de-convoluting the expression C(t)=R?(t)Cp?(t) with the arterial input function (AIF). A leakage rate or extravasation constant is determined directly from the tail part of the determined apparent residue function.

Abstract: The present invention relates to methods for the diagnosis of impaired cardiac function/heart disease. The present invention provides a method of diagnosing heart disease in a subject, said method comprising determining the level of CgB or SgII, or fragments thereof, in a body fluid of said subject. Such methods can also be used to determine the clinical severity or prognosis of heart disease in a subject.